This year’s San Antonio Breast Cancer Symposium® (SABCS) takes place December 5-9, 2023, and will feature a session focused on invasive lobular carcinoma (ILC) sponsored by the Lobular Breast Cancer Alliance (LBCA). In addition, LBCA is proud to be among the research poster presenters sharing the findings from our patient experience survey about surgery and ILC.
For those attending SABCS in person, LBCA invites you to stop by our booth (#1615). LBCA will also host a meet-up on how to navigate SABCS. Those wishing to take part can come to the Stars at Night ballroom after the ILC Educational Session that takes place on Tuesday, December 5, at 3:15pm. LBCA staff will meet you at the back of the ballroom (center door) to walk to the Patient Advocate Lounge. The Patient Advocate Lounge will be Room 225B at Henry B. Gonzalez Convention Center.
Here is the full list of ILC-focused posters that those who registered for this year’s SABCS can visit in person or virtually. Posters submitted by members of the LBCA Scientific Advisory Board (SAB) and/or LBCA’s grantees are highlighted in bold blue font in the list of poster authors below.
Poster Session 1: Wednesday, December 6 at 12pm CT
PO1-15-03 Spatially resolved analysis of tumor microenvironment in invasive lobular carcinoma.
Matteo Serra, Mattia Rediti, Laetitia Collet, Frédéric Lifrange, David Venet, Nicola Occelli, Xiaoxiao Wang, Delphine Vincent, Ghizlane Rouas, Ligia Craciun, Denis Larsimont, Laurence Buisseret, Miikka Vikkula, François Duhoux, Françoise Rothé, Christos Sotiriou. Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium, Belgium;9 Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Belgium; Institut Jules Bordet, Belgium; Department of Pathology, University Hospital Center of Liege, Liege, Belgium, Belgium; Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Cliniques universitaire Saint-Luc-institut Roi Albert II; Institut Jules Bordet.
Poster Session 2: Wednesday, December 6 at 5pm CT
PO2-07-09 Early stage invasive lobular breast cancer is underestimated on conventional imaging including MRI.
Kaat Van Herck, Karen Van Baelen, Chantal Van Ongeval, Valerie Celis, Helen De Boodt, Machteld Keupers, Renate Prevos, Giuseppe Floris, Ines Nevelsteen, Ann Smeets, Thaïs Baert, Sileny Han, Hans Wildiers, Annouschka Laenen, Christine Desmedt, Patrick Neven. KU Leuven; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium, Leuven, Vlaams-Brabant, Belgium; UZ Leuven; University Hospitals Leuven; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium; University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium; KULeuven; Laboratory for Translation Breast Cancer Research/KU Leuven, Leuven, Vlaams-Brabant, Belgium; Universitair Ziekenhuis Leuven, Leuven, Leuven, Vlaams-Brabant, Belgium.
PO2-11-09 European Lobular Breast Cancer Advocates: Bridging the Geographical Gaps in Lobular Breast Cancer Education and Awareness.
Siobhan Freeney, Helene Bonval, Esther Geven, Lori Petitti, Rian Terveer, Claire Turner, Cathrin Brisken, Patrick Derksen, Christine Desmedt, Thijs Koorman, Adrian Lee, Steffi Oesterreich, Anne Salomon, George Sflomos, Karen Van Baelen, Tone Lien, Damir Vareslija, Sabine Linn. Lobular Ireland, ELBCC; European Lobular Breast Cancer Advocates, France; European Lobular Breast Cancer Advocates, Netherlands; Breast Cancer Care & Research Fund, Santa Monica, California, United States; Lobular Breast Cancer UK, United Kingdom; ISREC – Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Division of Molecular Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Laboratory for Translation Breast Cancer Research/KU Leuven, Leuven, Vlaams-Brabant, Belgium; UMC Utrecht; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States; University of Pittsburgh, Pittsburgh, Pennsylvania, United States; Institut Curie; Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium, Leuven, Vlaams-Brabant, Belgium; European Lobular Breast Cancer Advocates, Norway; RCSI University of Medicine and Health Sciences Dublin; Netherlands Cancer Institute, Netherlands.
PO2-27-08 Discovery of glucocorticoid receptor-induced EMT and integrin gene expression and increased cell motility in invasive lobular breast cancer.
Baylee Porter, Candace Frerich, Muriel Laine, Sunati Sahoo, Geoffrey Greene, Jeon Lee, Lynda Bennett, Suzanne Conzen. UT Southwestern Medical Center, Dallas, Texas, United States; UT Southwestern Medical Center; The University of Chicago; University of Chicago, Chicago, Illinois, United States; UT Southwestern Medical Center, Dallas, Texas, United States.
Poster Session 3: Thursday, December 7 at 12pm CT
PO3-08-11 Association between Histologic Variants and the Results of Multigene Testing in Patients with Hormone Receptor-positive, HER2-negative Invasive Lobular Cancer.
Jee Hyun Ahn, Suk Jun Lee, Seung Hye Yang, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Byeong Woo Park, Seho Park. Yonsei University College of Medicine; Yonsei University College of Medicine; Yonsei University College of Medicine; Department of Surgery, Yonsei University College of Medicine.
PO3-18-08 Rational therapeutic combination of Bromodomain and Extra-Terminal domain (BET) inhibitor and Fibroblast Growth Factor Receptor (FGFR) inhibitor for treatment of invasive lobular carcinoma.
Binbin Gao, Elspeth Ward, Anna Blümel, Emer Conroy, Rachel Moore, Grainne Cremin, Rachel Bleach, Kathryn Haley, Tríona Ní Chonghaíle, Andreas Lindner, Jochen Prehn, Yi Zhang, Idalia Cruz, Leena Hilakivi-Clarke, Georgios Sflomos, Cathrin Brisken, William Gallagher, Darran O’Connor. Royal College of Surgeons in Ireland/School of Pharmacy and Biomolecular Sciences; Royal College of Surgeons in Ireland/School of Pharmacy and Biomolecular Sciences, Ireland; UCD/Conway Institute, Ireland; Royal College of Surgeons in Ireland/Department of Physiology & Medical Physics; Georgetown University/Lombardi Cancer Centre; Soochow University/College of Pharmaceutical Sciences; Univerity of Minnesota; ISREC – Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Royal College of Surgeons in Ireland/ School of Pharmacy and Biomolecular Sciences, Ireland.
PO3-28-01 More Than a Diagnosis: An Untold Story of Quality of Life.
Stacey Tinianov, Kelly Shanahan, Catherine Thomsen, Ginny Mason, Laura Carfang, Joanne Mika Hayashi, Laurie Hutcheson. Advocates for Collaborative Education, Santa Cruz, California, United States; Metavivor Research and Support; Zero Breast Cancer; IBC Research Foundation; Surviving Breast Cancer; Breast Cancer Hawaii; Lobular Breast Cancer Alliance Inc., Massachusetts, United States.
PO3-28-09 Does Diffusely Infiltrating Lobular Carcinoma of the Breast Arise from EpithelialMesenchymal Hybrid Cells?
Andras Voros, Laszlo Tabar, Renata Bozo, Orsolya Olah, Katalin Ormandi, Zoltan Vereb, Istvan Nemeth, Peter B. Dean, Olga Puchkova, MingFang Yen, Li-Sheng Chen. University of Szeged, Department of Pathology; Falun Central Hospital; University of Szeged, Department of Dermatology; University of Szeged, Department of Radiology; University of Turku, Department of Diagnostic Radiology; Il’inskaya Hospital, Department of Breast Imaging; Taipei Medical University, College of Oral Medicine.
Poster Session 4: Thursday, December 7 at 5pm CT
PO4-02-03 Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
Rita Mukhtar, Christina Yau, Denise Wolf, Adam Brufsky, Hannah Linden, Natasha Hunter, Reshma Mahtani, Abirami Sivapiragasam, Trevor Feinstein, Fengting Yan, Ian Grady, Priscilla McAuliffe, Michaela Tsai, Joyce O’Shaughnessy, Blanche Mavromatis, Sasha Davis, Josien Haan, William Audeh, Lavanya Samraj, FLEX Investigators’ Group. University of California, San Francisco; UCSF; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center; University of Washington, Fred Hutchison Cancer Center, Seattle, Washington, United States; Fred Hutchinson Cancer Center, Seattle, Washington, United States; Miami Cancer Institute; Upstate Medical University; Piedmont Cancer Institute; Swedish Medical Center, Washington, United States; North Valley Breast Clinic; UPMC Hillman Cancer Center; Swedish Medical Center, WA; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas, United States; UPMC Western Maryland; Texas Oncology, TX; Agendia NV; Agendia Inc.; Agendia.
PO4-02-04 Overall survival and disease recurrence rates in patients with invasive lobular breast cancer of the PenelopeB cohort.
Hervé Bonnefoi, Frederik Marmé, Miguel Martín, Michael Untch, Sung-Bae Kim, Harry Bear, Nicole McCarthy, Karen Gelmon, José Ángel García-Sáenz, Catherine M. Kelly, Toralf Reimer, Zhe Zhang, Masakazu Toi, Hope Rugo, Michael Gnant, Andreas Makris, Nader Hirmas, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl. Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC), France; Med. Fakultät Mannheim der Universität Heidelberg, Germany; Hospital General Universitario Gregorio Marañón, Spain; AGO-B and HELIOS Klinikum Berlin Buch, Berlin, Germany; Asan Medical Center, Seoul, Republic of Korea; Virginia Commonwealth University, Massey Cancer Center, Richmond, Virginia, United States; Breast Cancer Trials Australia and New Zealand and University of Queensland Australia; BC Cancer Agency, Vancouver, British Columbia, Canada; Hospital Clínico San Carlos, Madrid, Spain; Cancer Trials Ireland, Ireland; Breast Center, University of Rostock, Germany; Pfizer, San Diego, California, United States; Graduate School of Medicine, Kyoto University, Japan; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States; Medical University of Vienna, Austria; Mount Vernon Cancer Centre, Northwood, England, United Kingdom; German Breast Group, Neu-Isenburg, Germany; German Breast Group, Germany; German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany, Germany.
PO4-02-12 MDA iLobular Prognostic Tool: A Novel Approach for Risk Stratification in Invasive Lobular Carcinoma.
Jason Mouabbi, Sarah Pasyar, Roland Bassett, Akshara Singareeka Raghavendra, Amy Hassan, Rachel Layman, Debu Tripathy. The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; The University of Texas MD Anderson Cancer Center.
PO4-14-12 Predicting Response to HER2 Tyrosine Kinase Inhibitors and Antibody Drug Conjugates in HER2 Mutant Invasive Lobular Carcinoma Using CRISPR/Cas9 Knock-in Cell lines and Patient-derived Organoids.
Jie Bin Liu, Danielle Tseng, Jagmohan Hooda, Daniel Brown, Adrian Lee, Steffi Oesterreich. University of Pittsburgh; University of Pittsburgh, Pittsburgh, Pennsylvania, United States; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States.
PO4-17-03 Neoadjuvant chemotherapy in invasive lobular carcinoma of the breast: A retrospective study on survival outcomes.
Virginie Gauthier, Anne-Julie Simard, Christine Desbiens, Brigitte Poirier, Julie Lemieux, Dominique Boudreau, Dominique Leblanc, Claudya Morin, JeanCharles Hogue, Éric Poirier. CHU de Québec – Université Laval; Centre des maladies du sein du CHU de Québec-Université Laval, Hôpital St-Sacrement, Québec, Quebec, Canada.
PO4-19-03 FES-PET/MRI for Tailored treatment of luminal A and lobular breast cancer: a prospective cohort study.
Rosa Di Micco, Carla Canevari, Francesca Gallivanone, Nicole Rotmensz, Veronica Zuber, Sara Baleri, Giovanni Cisternino, Mario Rampa, Stefania Zambelli, Giulia Viale, Patrizia Zucchinelli, Manuela Morgante, Paola Scifo, Elena Venturini, Paola Magnani, Isabella Sassi, Vincenzo Bagnardi, Pietro Panizza, Giampaolo Bianchini, Arturo Chiti, Oreste Davide Gentilini. Breast Surgery Unit, San Raffaele University and Research Hospital (Milan, Italy), Italy; Nuclear Medicine Department, San Raffaele University and Research Hospital, Milan, Italy; IBFM-CNR Institute of Bioimaging and Molecular Physiology of the Italian National Research Council, Milan, Italy; Breast Surgery Unit, San Raffaele University and Research Hospital (Milan, Italy); Breast Surgery Unit, San Raffaele University and Research Hospital, Milan, Italy; Medical Oncology Department, San Raffaele University and Research Hospital, Milan, Italy; Nuclear Medicine Department, San Raffaele University and Research Hospital; Breast Radiology Unit, San Raffaele University and Research Hospital, Milan, Italy; Pathology Department, San Raffaele University and Research Hospital, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy; IRCCS Ospedale San Raffaele, Milan, Lombardia, Italy; Breast Surgery Unit, San Raffaele University Hospital, Italy.
PO4-28-09 Upregulation of the immune checkpoint protein B7-H3 is associated with an immune suppressive microenvironment in progression from in situ to invasive lobular breast cancer.
Lynda Bennett, Sunati Sahoo, Cheryl Lewis, Indu Raman, Candace Frerich, Guanchun Chen, Min Xu, Suzanne Conzen. UT Southwestern Medical Center, Dallas, Texas, United States; UT Southwestern Medical Center; UT Southwestern Medical Center.
Poster Session 5: Friday, December 8 at 12pm CT
PO5-02-13 Distinct differences in the prognostic implication of tumor size for invasive lobular carcinoma of breast when compared to invasive ductal carcinoma.
Ik Beom Shin, Eunhye Kang, Ji-Jung Jung, Hawjeong Lee, Jin Young Byeon, Yunhee Choi, Changjin Lim, Jong-Ho Cheun, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Hyeong-Gon Moon. Department of Surgery, Seoul National University Hospital; Seoul National Univ. Hospital, Surgery, Republic of Korea; Seoul National Univ. Hospital, Surgery, Korea; Medical Research Collaborating Center, Seoul National University Hospital; Seoul Metropolitan Government Seoul National University Boramae Medical Center; Seoul National University Hospital; Seoul National University Hospital, Republic of Korea; Seoul National University, Republic of Korea.
PO5-04-12 Comparison of chemotherapy efficacy in metastatic lobular vs. ductal breast cancer.
Brendan Kirwin, Arlene Chan. Royal North Shore Hospital; Breast Cancer Research Centre – Western Australia, Hollywood Consulting Centre, WA 6009, Nedlands, Western Australia, Australia.
PO5-06-14 Genomic Landscape and Clinical Outcomes of Triple-Negative Invasive Lobular Carcinoma.
Hemali Batra-Sharma, Smruthy Sivakumar, Prashanth Ashok Kumar, Ethan Sokol, Rebecca Shatsky, Jeffrey Ross. University of California San Diego Moores Cancer Center; Foundation Medicine Inc.; SUNY Upstate Medical University, Syracuse, New York, United States; Foundation Medicine Inc; University of California at San Diego.
PO5-13-12 Personalized circulating tumor DNA testing for recurrence detection and treatment response monitoring in patients with metastatic invasive lobular carcinoma.
Steffi Oesterreich, Antony Tin, Samuel Rivero-Hinojosa, Janie Fielder, Jenifer Ferguson, Ekaterina Kalashnikova, Angel Rodriguez, Minetta Liu, Adrian Lee. University of Pittsburgh, Pittsburgh, Pennsylvania, United States; Natera, Inc.; Natera INC; Natera, Inc; Natera, San Carlos, California, United States; Natera; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States.
PO5-24-11 An integrated approach for comprehensive molecular and tumor microenvironment characterization of invasive lobular carcinoma.
Jason Mouabbi, Konstantin Chernyshov, Oleg Baranov, Vladimir Kushnarev, Polina Turova, Anna Butusova, Sofia Menshikova, Jessica Brown, Nikita Kotlov, Patrick Clayton, Krystle Nomie, Nathan Fowler, Debu Tripathy. The University of Texas MD Anderson Cancer Center, Houston, Texas, United States; BostonGene, Corp.; BostonGene, Corp; BostonGene; BostonGene Corp.
PO5-26-07 Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
Laurie Hutcheson, Janice Axelrod, Tracy Cushing, Colleen Fitzwater, Rinath Jeselsohn, Gitte Joergensen, Maria Karsten, Miranda Kimm, Megan Kruse, Theresa Langdon, Julia Levine, Mason Mitchell-Daniels, Rita Mukhtar, Barbara Neilsen, Shani Paluch-Shimon, Therese Pross. Lobular Breast Cancer Alliance Inc., Massachusetts, United States; Lobular Breast Cancer Alliance Inc.; University of Colorado, Aurora CO; Dana-Farber Cancer Institute, Boston, Massachusetts, United States; Charité, Berlin; Williams College; Cleveland Clinic, Cleveland, Ohio, United States; Lobular Breast Cancer Alliance Inc., United States; University of California, San Francisco; Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, and Faculty of Medicine, Hebrew University, Israel; Charité – Universitätsmedizin Berlin, Germany.
